Background
Neuroinflammation and immune responses mediated by microglia are associated with brain injury after ischemic stroke, and it is novel that Cl− movement and Cl-sensitive signal pathways have been shown to be implicated in the survival and switch of inflammation patterns of immune cells. Swell1, one of the components of Volume-regulated Cl− currents (VRAC) is considered to be the main channels mediating Cl− efflux from nerves cells. However, the role of Swell11 in ischemia-induced inflammation and the effect of Swell1 on the inflammation patterns switch of microglia remain unknown.
Methods
Whole-cell patch clamp recordings was used to examine Swell1-mediated VRAC in BV2 cells. In vivo and vitro studies comparing EGFP and Swell1 conditional knock-in mice were performed to determine the role of microglia Swell1 on inflammation and brain injury after ischemic stroke. In vitro experiments to further explored the mechanism of microglia Swell1 in regulating neuroinflammation.
Results
Our data showed that knockdown or overexpression of Swell1 in cultured BV2 cells inhibited or increased hypotonic-activated Cl− currents, respectively, and these changes were completely blocked by the VRAC inhibitor DCPIB. Swell1 conditional knock-in mice promoted microglial survival in the lesion region, leading to reductions in neural cell apoptosis, infarction size and neurological deficits following transient middle cerebral artery occlusion (tMCAO). Using gene manipulating technique and pharmacological inhibitors, we further revealed that Swell1 opening led to SGK1 (a Cl−-sensitive kinase)-mediated activation of FOXO3a/CREB as well as WNK1 (another Cl−-sensitive kinase)-mediated SPAK/OSR1-CCCs activation, which promoted microglial survival and M2 polarization, thereby attenuating inflammation and ischemic brain injury.
Conclusion
Our results demonstrated that Swell1 is an essential component of microglia VRAC and its activation protects against ischemic brain injury through promoting microglial survival and M2 polarization, which provides new a new orientation for the treatment of ischemic stroke and other neurological diseases associated with inflammation.